Amgen (AMGN) Just Gave Investors Something To Think About
Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness
Is Amgen Stock Still Telling Investors The Same Thing?
Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Amgen’s acquired Sjögren’s drug a Phase III hit
Argus Research Maintains Buy on Amgen, Raises Price Target to $515
Amgen (AMGN) Stock Looks Cheap Based On Future Cash Flow
Amgen Reports Phase 3 Dazodalibep Trial Meets Primary Endpoint in Sjögren’s Disease
Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
Amgen Says Dazodalibep Met Primary Endpoint At Week 48
Explosive Options' Bob Lang on why he likes Amgen
Amgen’s Repatha shows cost-effectiveness in cardiovascular study
What Does Amgen (AMGN) Mean For Heart Attack Risk After New Repatha Data?
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen's new drug could mean fewer shots for obesity patients
Amgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today
Freedom Broker Downgrades Amgen to Hold, Raises Price Target to $470
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.